Brief: Voyager Therapeutics Announces First Participants Dosed In Dose Trial Of Vy-Tau01 For Treatment Of Alzheimer’s Disease
16/05/2024 12:12
May 16 (Reuters) - Voyager Therapeutics Inc VYGR.O :
* VOYAGER THERAPEUTICS ANNOUNCES FIRST PARTICIPANTS DOSED IN
SINGLE ASCENDING DOSE TRIAL OF VY-TAU01 FOR THE TREATMENT OF
ALZHEIMER’S DISEASE
* VOYAGER AIMS FOR INITIAL TAU PET IMAGING DATA BY SECOND
HALF OF
2026
Source text for Eikon: ID:nGNXbs5HMG
Further company coverage: VYGR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Voyager Therapeutics
See all newsBrief: Voyager Names Robin Swartz As President; Expected To Succeed As CEO In Q1 2027
Voyager Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Voyager Therapeutics Q2 collaboration revenue falls, net loss narrows
Brief: Voyager Therapeutics Q2 Net Income USD -24.473 Million
Voyager Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview